Mid Diagnosed 2026-09-28 11:50:32 KST
M
MRK AI Stock Diagnostic Report
Merck signs up to $2.13B license deal with SciBrunch Merck expanded its oncology pipeline by signing an exclusive global license agreement with SciBrunch for the KRAS G12D inhibitor SPR2015, worth up to $2.13 billion.
View Source Article ↗ AI CATALYST SCORE 68 / 100 Score computed by Sentinel V12
REFERENCE PRICE Not measured Reference entry price at analysis time
AI REFERENCE SCORE A reference score computed by the analysis engine from news and filings.
Report Info
Tier Mid
Diagnosed At 2026-09-28 11:50:32
Content Review Reviewed
Company Facts
Next Ex-Dividend Date Collecting
Next Earnings Date Collecting
Latest SEC Filing 2026-10-01T13:52:06-04:00 Data Composition Shows Sentinel V12's AI analysis, plus (for S-Class) Python Engine technical indicators and stored OHLC data.
+ ANALYSIS HISTORY
MRK Analysis History (Last 30 Days)